◆ mixed
Impact
PhasePhase 2
Time to marketDabogratinib is in Phase 2 development across all three indications. A pivotal Phase 3 study in NMIBC is being planned following the SURF302 data, but no specific start date has been given. The earliest potential approval would likely be several years away, contingent on successful Phase 3 data and FDA review.
dabogratinib Updated Nov 11
What to watch
The next hard catalyst is the BEACH301 Phase 2 safety sentinel cohort data in pediatric achondroplasia, expected by end of Q1 2027. Positive safety and growth data could re-rate the stock after the September 2026 SURF302 selloff; negative safety signals would damage the achondroplasia thesis. Separately, watch for details on a planned pivotal Phase 3 study in NMIBC, which would be the next major binary event for the bladder cancer program.
Bull case
- Initial SURF302 Phase 2 data showed a 79% overall response rate and 64% complete response rate at 60 mg QD in FGFR3-altered LG IR NMIBC, with a clean safety profile (no hyperphosphatemia, nail or ocular toxicity; Grade 3 AEs in <5% of patients).
- Dabogratinib is designed to be more FGFR3-selective than J&J's Balversa (erdafitinib), potentially avoiding the class-wide toxicities that limit existing FGFR inhibitors.
- Analyst consensus is strongly bullish: 10 Buy vs 2 Hold (0 Sell), with a mean price target of $47.45, implying ~113% upside from the current ~$20.97 price.
Bear case
- The stock dropped ~30% on September 9, 2026 after initial SURF302 Phase 2 data, suggesting the market expected stronger efficacy despite a 79% ORR and 64% CR rate. Investor skepticism about the drug's profile persists.
- Dabogratinib is Tyra's only clinical-stage asset; any clinical setback would leave the company with no pipeline, making it a high-risk single-asset story.
- Several large institutional holders trimmed or exited in Q2/Q3 2026, including Farallon Capital Management (exit), Balyasny (exit), and Barclays (near-exit), signaling mixed conviction.